Plasma EBV DNA As a Prognostic Factor in EBV Associated Gastric Cancer: a Multicenter, Prospective Study (EBV PRESAGE Study)

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Nov 9

PMID 37941551

Authors

Andrea Alberti

Gertraud Stocker

Florian Lordick

Ulrich T Hacker

Benjamin Kobitzsch

Ivonne Haffner

Gian Luca Baiocchi

Manuel Zamparini

Guido A M Tiberio

Carla Baronchelli

Arnaldo Caruso

Paolo Bossi

Alfredo Berruti

Affiliations

Soon will be listed here.

Abstract

Purpose: The Cancer Genome Atlas Research Network identified Epstein-Barr-Virus (EBV)-positive gastric cancer as a distinct molecular subtype. The prevalence is 8-9% and the histological examination shows pronounced lymphocytic infiltration, elevated levels of IFN-γ and consequently overexpression of PD-L1. The role of plasma EBV DNA load as a prognostic factor in patients with this cancer subtype is still to be defined.

Methods And Analysis: The present multicenter prospective observational study "EBV PRESAGE", involving German and Italian cancer centers, aims to evaluate the prognostic role of plasma EBV DNA in EBV-related gastric cancer (GC). The objective is to study the association between plasma EBV DNA load at different consecutive time points and the patient's prognosis. Every patient with a new diagnosis of gastric cancer (including gastroesophageal junction adenocarcinoma) will be screened for Epstein-Barr encoded small Region (EBER) on tissue biopsies using hybridization (ISH). If EBER ISH is positive, blood analysis for plasma EBV DNA will be conducted. The plasma EBV quantitative analysis will be centralized, and extraction, detection, and quantification of EBV DNA in plasma samples will be performed using real-time PCR.

Discussion: We hypothesized that plasma EBV DNA represents a non-invasive tool for monitoring EBV-related GC and might be valuable as a prognostic marker.

Citing Articles

Hodgkin lymphoma: the role of EBV plasma viral load testing in an HIV-endemic setting.

Opie J, Mohamed Z, Chetty D, Bailey J, Brown K, Verburgh E Clin Exp Med. 2024; 25(1):10.

PMID: 39589446 PMC: 11599344. DOI: 10.1007/s10238-024-01524-8.

References

Liu X, Liu J, Qiu H, Kong P, Chen S, Li W . Prognostic significance of Epstein-Barr virus infection in gastric cancer: a meta-analysis. BMC Cancer. 2015; 15:782. PMC: 4619309. DOI: 10.1186/s12885-015-1813-9. View

Lin J, Wang W, Chen K, Wei Y, Liang W, Jan J . Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004; 350(24):2461-70. DOI: 10.1056/NEJMoa032260. View

Horie Y, Miura K, Matsui K, Yukimasa A, Ohi S, Hamamoto T . Marked elevation of plasma carcinoembryonic antigen and stomach carcinoma. Cancer. 1996; 77(10):1991-7. DOI: 10.1002/(SICI)1097-0142(19960515)77:10<1991::AID-CNCR5>3.0.CO;2-K. View

. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513(7517):202-9. PMC: 4170219. DOI: 10.1038/nature13480. View

Leung S, Chan K, Ma B, Hui E, Mo F, Chow K . Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma. Ann Oncol. 2014; 25(6):1204-8. DOI: 10.1093/annonc/mdu117. View

Kijima Y, Ishigami S, Hokita S, Koriyama C, Akiba S, Eizuru Y . The comparison of the prognosis between Epstein-Barr virus (EBV)-positive gastric carcinomas and EBV-negative ones. Cancer Lett. 2003; 200(1):33-40. DOI: 10.1016/s0304-3835(03)00410-5. View

Hohaus S, Santangelo R, Giachelia M, Vannata B, Massini G, Cuccaro A . The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma. Clin Cancer Res. 2011; 17(9):2885-92. DOI: 10.1158/1078-0432.CCR-10-3327. View

Zhang Y, Li W, Mao Y, Guo R, Tang L, Peng H . Risk stratification based on change in plasma Epstein-Barr virus DNA load after treatment in nasopharyngeal carcinoma. Oncotarget. 2016; 7(8):9576-85. PMC: 4891061. DOI: 10.18632/oncotarget.7083. View

Qiu M, He C, Lu S, Guan W, Wang F, Wang X . Prospective observation: Clinical utility of plasma Epstein-Barr virus DNA load in EBV-associated gastric carcinoma patients. Int J Cancer. 2019; 146(1):272-280. DOI: 10.1002/ijc.32490. View

10.

Song H, Srivastava A, Lee J, Kim Y, Kim K, Kang W . Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma. Gastroenterology. 2010; 139(1):84-92.e2. DOI: 10.1053/j.gastro.2010.04.002. View

11.

Chang M, Lee H, Kim C, Kim Y, Kim W . Clinicopathologic characteristics of Epstein-Barr virus-incorporated gastric cancers in Korea. Pathol Res Pract. 2001; 197(6):395-400. DOI: 10.1078/0344-0338-00052. View

12.

Masetti M, Lindinger M, Lorenzen S . Programmed Cell Death Protein 1 Blockade Elicits Ongoing Remission in 2 Cases of Refractory Epstein-Barr Virus-Associated Metastatic Gastric Carcinoma. Oncol Res Treat. 2022; 45(6):375-379. DOI: 10.1159/000523754. View

13.

Roh C, Choi Y, Choi S, Seo W, Cho M, Jang E . Single Patient Classifier Assay, Microsatellite Instability, and Epstein-Barr Virus Status Predict Clinical Outcomes in Stage II/III Gastric Cancer: Results from CLASSIC Trial. Yonsei Med J. 2019; 60(2):132-139. PMC: 6342711. DOI: 10.3349/ymj.2019.60.2.132. View

14.

van Beek J, Zur Hausen A, Kranenbarg E, van de Velde C, Middeldorp J, van den Brule A . EBV-positive gastric adenocarcinomas: a distinct clinicopathologic entity with a low frequency of lymph node involvement. J Clin Oncol. 2004; 22(4):664-70. DOI: 10.1200/JCO.2004.08.061. View

15.

Mihmanli M, Dilege E, Demir U, Coskun H, Eroglu T, Uysalol M . The use of tumor markers as predictors of prognosis in gastric cancer. Hepatogastroenterology. 2004; 51(59):1544-7. View

16.

Marrelli D, Pinto E, De Stefano A, Farnetani M, Garosi L, Roviello F . Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg. 2001; 181(1):16-9. DOI: 10.1016/s0002-9610(00)00549-3. View

17.

Lee J, Kim S, Han S, An J, Lee E, Kim Y . Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: a meta-analysis. J Gastroenterol Hepatol. 2009; 24(3):354-65. DOI: 10.1111/j.1440-1746.2009.05775.x. View

18.

Chiaravalli A, Feltri M, Bertolini V, Bagnoli E, Furlan D, Cerutti R . Intratumour T cells, their activation status and survival in gastric carcinomas characterised for microsatellite instability and Epstein-Barr virus infection. Virchows Arch. 2005; 448(3):344-53. DOI: 10.1007/s00428-005-0066-4. View

19.

Park E, Do I, Park C, Kang W, Noh J, Sohn T . Cyclooxygenase-2 is an independent prognostic factor in gastric carcinoma patients receiving adjuvant chemotherapy and is not associated with EBV infection. Clin Cancer Res. 2009; 15(1):291-8. DOI: 10.1158/1078-0432.CCR-08-0848. View

20.

Truong C, Feng W, Li W, Khoury T, Li Q, Alrawi S . Characteristics of Epstein-Barr virus-associated gastric cancer: a study of 235 cases at a comprehensive cancer center in U.S.A. J Exp Clin Cancer Res. 2009; 28:14. PMC: 2642773. DOI: 10.1186/1756-9966-28-14. View